Investigational drug · Phase 2
SXR1096
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Netherton Syndrome.
Phase 2Last checked: Nov 20, 2026Latest source record: Dec 16, 2025 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
0 still active
All registered trials
1
Any phase or sponsor naming "SXR1096"
First trial start
2021
Dec 7, 2021
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "SXR1096", any sponsor or status.
Conditions studied
As listed on its trial records.
- Netherton Syndrome
Approved drugs for the same conditions: Rare and genetic disease
Largest trials
Live from ClinicalTrials.gov: studies naming "SXR1096" as an intervention, largest first.
Sixera PharmaIndustry
NCT05211830 · 9 participants · Start Dec 7, 2021 · Primary completion Jun 10, 2025
Drug: SXR1096 cream; Placebo cream · For: Netherton Syndrome
Sites: Innsbruck, Austria; Paris, France; Freiburg im Breisgau, Germany · 5 sites in all
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Netherton Syndrome
- QRX003Phase 33 trials
Quoin Pharmaceuticals · Netherton Syndrome
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.